ArticleMedicine2026
Unilateral biportal endoscopic lumbar interbody fusion: Radiographic and clinical outcomes in grade I lumbar spondylolisthesis.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
To evaluate the radiographic and clinical outcomes of unilateral biportal endoscopic lumbar interbody fusion (ULIF) in patients with grade I lumbar spondylolisthesis, 30 patients underwent ULIF between January 2023 and January 2024. Clinical and radiographic outcomes were analyzed, including operative time, intraoperative blood loss, hospital stay, fusion rate, and laboratory indices (Hb, CRP, CPK). All procedures were successfully completed without intraoperative complications. The mean operative time was 199.7 ± 36.5 minutes, blood loss 60.7 ± 29.6 mL, and hospital stay 9.2 ± 3.7 days. Low back pain Visual Analogue Scale decreased from 6.63 ± 1.00 to 0.83 ± 0.80, leg pain Visual Analogue Scale from 6.47 ± 1.41 to 0.63 ± 0.67, and Oswestry Disability Index from 58.47 ± 12.86 to 18.87 ± 7.67 at 12 months. The fusion rate at final follow-up was 100%. Laboratory findings indicated a transient decrease in Hb and increases in CRP and CPK on POD1, with recovery by POD3. ULIF is a promising short-term option for grade I lumbar spondylolisthesis, demonstrating effective reduction, spinal decompression, minimal soft tissue injury, and high short-term fusion success.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.